Methotrexate in the therapy of gastrointestinal diseases;Methotrexat in der therapie gastrointestinaler erkrankungen

Zeitschrift fur Gastroenterologie

Volumn 37, Issue 7, 1999, Pages 623-637

  Schroder O ^a   Stein, J ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Inflammatory bowel disease; Methotrexate; Primary biliary cirrhosis; Therapy

Indexed keywords

4 AMINOBENZOIC ACID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPHOTERICIN B; BARBITURIC ACID DERIVATIVE; CISPLATIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN; METHOTREXATE; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYTOIN; SALAZOSULFAPYRIDINE; SULFONAMIDE; TETRACYCLINE;

CANCER; CLINICAL TRIAL; CYTOPENIA; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG TRANSFORMATION; ENTERITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MUCOSA INFLAMMATION; NEPHROTOXICITY; NEUROTOXICITY; PRIMARY BILIARY CIRRHOSIS; REVIEW;

EID: 0345035314     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Smith JM Jr, Cosulich DB, Hultquist ME, Seeger DR. The chemistry of certain pteroylglutamic acid antagonists. Trans NY Acad Sci 1948; 10: 82-3
2. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff JA. Temporary remissions in acute leucemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948; 238: 787-93
3. Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1931; 221: 176-82
4. Rees RB, Bennett JH, Bostick WL. Aminopterin for psoriasis. Arch Dermatol 1955; 72: 133-43
5. Schröder O, Stein J. Methotrexat in der Therapie chronisch-entzündlicher Darmerkrankungen. Z Gastroenterol 1996; 34: 457-8
6. Kozarek RA, Patterson DJ, Gelfand MD et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353-6
7. Baron TH, Truss CD, Elson CO. Low-dose methotrexate in refractory inflammatory bowel disease. Dig Dis Sci 1993; 38: 1851-6
8. Lemann M, Chamiot-Pricur C, Mesnard B et al. Methotrexate for the treatment of refractory Crohn's disease (CD). Aliment Pharmacol Ther 1996; 10: 309-14
9. Arora S, Katkov WN, Cooley J et al. A double-blind, randomized placebo-controlled trial of methotrexate in Crohn's disease. Gastroenterology 1992; 102: A591
10. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7
11. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology 1991; 101: 1332-8
12. Kaplan MM, DeLellis RA, Wolfe HJ. Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann Intern Med 1997; 126: 682-8
13. Weber P, Scheurlen M, Wiedmann K-H. Methotrexat in der Therapie der primären biliären Zirrhose. DMW 1991; 116: 1347-52
14. Bergasa NV, Jones EA, Kleiner DE et al. Pilot study of low-dose oral methotrexate treatment for primary biliary cirrhosis. Am J Gastroenterol 1996; 92: 295-9
15. Lindor KD, Dickson ER, Jorgennen RA et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: The results of a pilot study. Hepatology 1995; 22: 1158-62
16. Gonzales-Koch A, Brahm J, Antezana C, Smok G, Cumsille MA. The combination of ursodeoxycholic acid and methotrexate for primary billiary cirrhosis is not better than ursodeoxycholic acid alone. J Hepatol 1997; 27: 143-9
17. Jolivet J, Cowan KH, Curt GA, Clendeninn NJ, Chabner BA. The pharmacology and clincial use of methotrexate. N Engl J Med 1983; 309: 1094-104
18. 3-pteroyl-glutamate-5 to dihydrofolate reductase. J Clin Invest 1983; 72: 773-8
19. Bagott JE, Vaughn WH, Hudson BB. Inhibition of 5-aminoimidazol-4-carboxamide ribotide transformylase, adenosine deaminase and 5'-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 1986; 236: 193-200
20. Seideman P, Beck O, Eksborg S, Wennberg M. The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35: 409-12
21. Bagott JE, Morgan SL, Vaughn WH. Differences in methotrexate and 7-hydroxymethotrexate inhibition of folate-dependent enzymes of purine nucleotide biosynthesis. Biochem J 1994; 300: 627-9
22. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 1993; 28: 466-9
23. Shiroky JB, Neville C, Edaile JM et al. Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: Results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 1993; 36: 795-803
24. Galivan J, Rehder MC, Kerwar S. Methotrexate in adjuvant arthritis. In: Cooper BA, Whitehead MV (eds.). Chemistry and Biology of Pteridines. Berlin, Walter de Cryter, 1986, 847-50
25. Weinstein GD, Jeffes E, McCullough JL. Cytotoxic and immunologic effects of methotrexate in psoriasis. J Invest Dermatol 1990; 95: 49-52
26. Johnston C, Russell AS, Kovithavongs T, Dasgupta M. Measures of immunologic and inflammatory responses in vitro in rheumatoid patients treated with methotrexate. J Rheumatol 1986; 13: 294-6
27. Olsen JN, Murray LM. Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 1989; 32: 378-85
28. Johnston C, Russell AS, Aaron S. The effect of in vivo and in vitro methotrexate on lymphocyte proliferation as measured by the uptake of tritiated thymidine and tritiated guanosine. Clin Exp Rheumatol 1988; 6: 391-3
29. Olsen NJ, Callahan LF, Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1987; 30: 481-8
30. Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992; 16: 411-23
31. Brody M, Bohm I, Bauer R. Mechanism of action of methotrexate: Experimental evidence that methotrexate blocks the binding of interleukin 1β to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 1993; 31: 667-74
32. Kremer JM. The mechanism of action of methotrexate in rheumatoid arthritis: The search continues. J Rheumatol 1994; 21: 1-5
33. Becker C, Barbulescu K, Hildner K, Meyer zum Büschenfelde K-H, Neurath MF. Activation and methotrexate-mediated suppression of the TNFα promoter in T-cells and macrophages. Ann N Y Acad Sci 1998; 17: 219-22
34. 4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 1992; 35: 376-84
35. Nesher G, Moore TL. The in vitro effects of methotrexate on peripheral blood mononuclear cells: Modulation by methyl donors and spermidine. Arthritis Rheum 1990; 33: 954-9
36. Cronstein BN, Eberle MA, Gruber HE, Levin RI. Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 1991; 88: 2441-5
37. Cronstein BN, Naime D, Ostad E. The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leucocyte accumulation in an in vivo model of inflammation. J Clin Invest 1993; 92: 2675-82
38. Selhub J, Dhar GJ, Rosenberg IH. Gastrointestinal absorption of folates and antifolates. Pharmacol Ther 1993; 20: 397-418
39. Zimmermann J. Methotrexate transport in the human intestine: Evidence for heterogeneity. Biochem Pharmacol 1992; 43: 2377-83
40. Teresi ME, Crom WR, Choi KE, Mirro J, Evans WE. Methotrexate bioavailability after oral and intramuscular administration in children. J Pediatr 1987; 110: 788-92
41. Herman RA, Veng-Pedersen P, Hoffman J, Koehnke R, Furst De. Pharmacokinctics of low-dose methotrexate in rheumatoid arthritis patients. Pharm Sci 1989; 78: 165-71
42. Oguey D, Kölliker F, Gerbern NJ, Reichen J. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 611-4
43. Jundt JW, Browne BA, Fiocco GP, Steele Ad. Mock D. A comparison of low-dose methotrexate bioavailability: Oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 1845-59
44. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route and administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974; 34: 3487-91
45. Kearney PJ, Light PA, Preece A, Mott MG. Unpredictable serum levels after oral methotrexate in children with acute lympboblastic leukemia. Cancer Chemother Pharmacol 1979; 3: 117-20
46. Lebbe C, Beyeler C, Gerber NJ, Reichen J. Intra-individual variability of the bioavailability of low-dose methotrexate after oral administration in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 475-7
47. Brooks PL, Spruill WJ, Parish RC et al. Pharmacokinetics of methotrexate administered by intra-muscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 91-4
48. Moshkowitz M, Oren R, Tishler M et al. The absorption of low-dose methotrexate in patients with inflammatory disease. Aliment Pharmacol Ther 1997; 11: 569-73
49. Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ (eds.). Applied pharmacokinetics: Principle of drug monitoring. Chap 29. Vancouver. Applied Pharmacokinetics 1992; 1-42
50. Claudepierre P, Urien S, Chevalier X et al. Methotrexate serum binding in rheumatoid arthritis. Int J Clin Pharmacol Ther 1994; 32: 113-5
51. Furst DE, Herman RA, Koehnke R et al. Effect of aspirin and sulindac on methotrexate clearance. J Pharm Sci 1990; 79: 782-6
52. Huffman DH, Wan SH, Azarnoff DL, Hogstraten B. Pharmacokinetics of methotrexate. Clin Pharmacol Ther 1973; 14: 572-9
53. Lippens RJ. Methotrexate. I. Pharmacology and pharmacokinetics. Am J Pediatr Hematol Oncol 1984; 6: 379-95
54. Schroder H, Fogh K. Methotrexate and its polyglutamate derivatives in erythrocytes during and after weekly low-dose oral methotrexate therapy of children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 1988; 21: 145-9
55. Schroder H, Fogh K, Herlin T. In vivo decline of methotrexate and methotrexate polyglutamates in age-fractionated erythrocytes. Cancer Chemother Phramcol 1988; 21: 150-15
56. Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet 1978; 3: 1-13
57. Seideman P, Beck O, Eksborg S et al. The pharmacokineties of methotrexate and its 7-hydroxymetabolite in patients with rheumatoid arthritis. Br J Clin Pharmacol 1993; 35: 409-12
58. Kremer JM, Petrillo GF, Hamilton RA. Examination of pharmacokinetic variables in a cohort of patients with rheumatoid arthritis beginning therapy with methotrexate compared with a cohort receiving the drug for a mean of 81 months. J Rheumatol 1995; 22: 41-4
59. Nuernberg B, Kohnke R, Solsky M et al. Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 1990; 33: 898-902
60. Evans WE, Christensen ML. Drug interactions with methotrexate. J Rheumatol 1985; 12: 15-20
61. Slordal L, Sager G, Aarbakke J. Pharmacokinetic interactions with methotrexate: Is 7-OH-methotrexate the culprit? Lancet 1988; 1: 591-2
62. Frenia ML, Long KS. Methotrexate and non-steroidal antiinflammatory drug interactions. Ann Pharmacother 1992; 26: 234-7
63. Tracy TS, Krohn K, Jones DR et al. The effects of a salicylate, ibuprofen, and naproxen on the disposition of methotrexate in patients with rheumatoid arthritis. Eur J Clin Pharm 1992; 42: 121-5
64. Steward CF, Fleming RA, Germain BF, Seleznick MJ, Evans WE. Aspirin alters methotrexate disposition in rheumatoid arthritis patients. Arthritis Reum 1991; 34: 1514-20
65. Lafforgue P, Monjanel-Mouterde S, Durand A, Catalin J, Acquaviva PC. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? J Rheumatol 1993; 20: 263-7
66. Liegler DG, Henderson ES, Hahn MA, Aliverio VT. The effect of organic acids on renal clearance of methotrexate. Clin Pharmacol Ther 1969; 10: 849-57
67. Aherne GW, Piall E, Marks V. Prolongation and enhancement of serum methotrexate concentrations by probenicid. BMJ 1978; 1: 1097-9
68. Jeurissen ME, Boerbooms AM, van de Putte LB. Pancytopenia and methotrexate with trimetoprim/sulfamethoxazole. Ann Intern Med 1989; 111: 261
69. Goenendal H, Ramper FHJ. Methotrexate and trimetoprim sulfamethoxazole - a potentially hazardous combination. Clin Exp Dermatol 1990; 15: 358-60
70. Cannon GW, Ward JR, Clegg DO, Samuelson CO, Abbott TM. Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 1983; 26: 1269-74
71. Nisar M, Carlisle L, Amos RS. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis. Br J Rheumatol 1993; 20: 263-7
72. Balis FM, Holcenberg JS, Zimm S et al. The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987; 41: 384-7
73. Korstanje MJ. van Breda Vriesman CJ. van de Staak WJ. Cyclosporine and methotrexate: A dangerous combination. J Am Acad Dermatol 1990; 23: 320-1
74. Scully CJ, Anderson CJ, Cannon GW. Long-term methotrexate for rheumatoid arthritis. Semin Arthritis Rheum 1991; 20: 317-31
75. Lewis JH, Schiff L. Methotrexate-induced chronic liver injury: Guidelines for detection and prevention. Am J Gastroenterol 1988; 83: 1337-45
76. Kremer JM, Lee RG, Tolman KG. Liver histology in rheumatoid arthritis patients receiving long-term methotrexate therapy: A prospective study with baseline and sequential biopsy samples. Arthritis Rheum 1989; 32: 121-7
77. Podurgiel BJ, McGill DB, Ludwig J, Taylor WF, Muller SA. Liver injury associated with methotrexate therapy for psoriasis. Mayo Clin Proc 1973; 48: 787-92
78. Bannwarth B, Labat L, Moride Y, Schaeverbeke T. Methotrexate in rheumtoid arthritis. An update. Drugs 1994; 47: 25-50
79. Beyeler C. Methotrexat-Behandlung der rheumatoiden Arthritis. Schweiz Med Wochenschr 1996; 126: 703-12
80. Kremer JM, Alarcon GS, Lightfoot RW Jr et al. Methotrexate for rheumatoid arthritis: Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 316-28
81. Schnabel A, Gross WL. Low-dose methotrexate in rheumatic diseases - efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994; 23: 310-27
82. Goodman TA, Polisson RP. Methotrexate: Adverse reactions and major toxicities. Rheum Dis Clin North Am 1994; 20: 513-28
83. Trier JS. Morphological alterations induces by methotrexate in the mucosa of human proximal intestine. I. serial observations by light microscopy. Gastroenterology 1962; 42: 295-305
84. Phelan MJ, Taylor W, van Heyningen C, Williams E. Thompson RN. Intestinal absorption in patients with rheumatoid arthritis treated with methotrexate. Clin Rheumatol 1993; 12: 223-5
85. Baker H. Intermittent high-close oral methotrexale therapy in psoriasis. Br J Dermatol 1970; 82: 65-9
86. Atherton LD, Leib LS, Kaye MD. Toxic megacolon associated with methrotrexate therapy. Gastroenterology 1984; 86: 1583-8
87. Rau R. Methrotrexatbehandlung der chronisehen Polyarthritis 1994 - Line Übersicht. Z Rheumatol 1994; 53: 199-229
88. Barrera P, Laan RFJM, van Riel PLCM et al. Methotrexate-related pulmonary complications in rheumatoid arthritis. Ann Rheum Dis 1994; 53: 434-9
89. Cannon GW. Antirheumatic drug reactions in the lung. Baillieres Clin Rheuamtol 1993; 7: 147-71
90. Bleyer WA. The clinical pharmacology of methotrexate. New applications of an old drug. Cancer 1978; 41: 36-51
91. Seideman P, Müller-Suur R, Ekman E. Renal effects of low-dose methotrexate in rheumatoid arthritis. J Rheumatol 1993; 20: 1126-8
92. Weinblatt ME, Trentham DE, Fraser PA. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988; 31: 167-75
93. Vogelsang SA, West SG, Sigleton JD, Enzenauer RJ. Long-term toxicity and efficacy of methotrexate in rheumatoid arthritis patients. Arthritis Rheum 1990; 33: S62
94. Morris LF, Harrod MJ, Menter AM, Silverman AK. Methotrexate and reproduction in men: Case report and recommendations. J Am Acad Dermatol 1993; 29: 913-6
95. Sussman A, Leonard JM. Psoriasis, methotrexate and oligospermia. Arch Dermatol 1980; 116: 215-7
96. Furst DE. The rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases. Br J Rheumatol 1997; 36: 1196-204
97. Adult and two children with fetal methotrexate syndrome. Teratology 1998; 57: 51-5
98. Rustin GJS, Rustin F, Dent J et al. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med 1983; 308: 473-6
99. Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138-45
100. Weinblatt ME, Kaplan H, Germain BF. Methotrexate in rheumatoid arthritis: Effects on disease activity in a multicenter prospective study. J Rheumatol 1991; 18: 334-8
101. Wernick R, Smith DL. Central nervous system toxicity associated with weekly low-dose methotrexate therapy. Arthritis Rheum 1989; 32: 770-5
102. Vandeputte L, D'Haens G. Baert F, Rutgeerts P. Methotrexate in refractory Crohn's disease. Inflamm Bowel Dis 1999; 5: 11-5
103. Oren R, Arber N, Odes S et al. Methotrexate in chronic active ulcerative colitis: A double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 1416-21
104. Oren R, Moshkowitz M, Becker S et al. Methotrexate in chronic active Crohn's disease: A double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 2203-9
105. Kaplan MM, Knox TA, Arora S. Primary biliary cirrhosis treated with low-dose oral pulse methotrexate. Ann Intern Med 1988; 109: 429-31